Clinical trials: Metastatic Castration-resistant Prostate Cancer, mCRPC
- Condition Metastatic Castration-resistant Prostate Cancer, mCRPC
- Funder type Industry (pharma, biotech, devices)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10, GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06344715
- Testing
- SL-T10, GX-I7, Pembrolizumab
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- SL VAXiGEN
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
ACCEL is a multicenter, open label phase Ia/Ib/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Oligometastatic Prostate Carcinoma, Hormone Sensitive Prostate Cancer
- Trial name
- ACCEL (NCT06229366)
- Testing
- [Ac-225]-PSMA-62 (mCRPC), [Ac-225]-PSMA-62 (OmHSPC)
- Where
- 7 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
This protocol is designed to provide participants currently benefiting from rucaparib treatment in a Clovis-sponsored clinical study with continued access to treatment for as long as they continue to benefit.
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CATCH-R (NCT04676334)
- Testing
- Rucaparib
- Where
- 25 sites in Canada, Israel and 4 more
- Volunteers
- 34 people
- Sponsor
- pharmaand GmbH
Metastatic Castration-resistant Prostate Cancer
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.
- Trial name
- NCT03692663
- Testing
- TABP EIC, Cyclophosphamide, fludarabine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Metastatic Castration-Resistant Prostate Cancer
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants…
- Trial name
- NCT06842498
- Testing
- FG-3246
- Where
- 23 sites in United States
- Volunteers
- 75 people
- Sponsor
- Kyntra Bio
Prostatic Neoplasms, Castration-Resistant
Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )
Categorize the clinical parameters and patient determinants that drive physician decision making for treatment selection including Radium-223 for patients with mCRPC.
- Trial name
- Navigant (NCT02899104)
- Testing
- Xofigo (Radium-223 dichloride, BAY88-8223)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Bayer
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
This study is researching a new drug called REGN15505 when used alone or in combination with cemiplimab or in combination with REGN4336 in adult patients with mCRPC and ccRCC.
- Trial name
- NCT07594106
- Testing
- REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336
- Where
- 6 sites in United States
- Volunteers
- 265 people
- Sponsor
- Regeneron Pharmaceuticals
Metastatic Castration Resistant Prostate Cancer
Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC
This study will treat patients with Metastatic Castration Resistant Prostate Cancer who have progressed following prior therapy.
- Trial name
- NCT04634344
- Testing
- DZD2269
- Where
- 6 sites in United States, South Korea
- Volunteers
- 16 people
- Sponsor
- Dizal Pharmaceuticals
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT06801236
- Testing
- ACE-232 tablets
- Where
- 13 sites in United States, China
- Volunteers
- 88 people
- Sponsor
- Acerand Therapeutics (Hong Kong) Limited
Prostate Cancer Castration-resistant Prostate Cancer
A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC
The aim of this trial is to evaluate the Drug-Drug interaction with Abiraterone combined with SHR3162 in the Metastatic Castration Resistant Prostate Cancer Patients.
- Trial name
- NCT04108247
- Testing
- Abiraterone+SHR3162
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Metastatic Castration Resistant Prostate Cancer
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.
- Trial name
- TRITON2 (NCT02952534)
- Testing
- Rucaparib
- Where
- 149 sites in United States, Australia and 10 more
- Volunteers
- 277 people
- Sponsor
- pharmaand GmbH
Prostate Cancer
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with…
- Trial name
- NCT02130700
- Testing
- VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Innocrin Pharmaceutical
mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)
- Trial name
- P300 (NCT06785636)
- Testing
- Pocenbrodib, Pocenbrodib and Darolutamide
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- Pathos AI, Inc.
Metastatic Castration-Resistant Prostate Cancer
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, Phase 1, dose escalation and dose confirmation study of ZEN003694 in patients with mCRPC.
- Trial name
- NCT02705469
- Testing
- ZEN003694
- Where
- 8 sites in United States
- Volunteers
- 44 people
- Sponsor
- Zenith Epigenetics
Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,
Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.
To investigate the safety, tolerability and anti-tumour activity of AZD5363, as monotherapy, in patients with metastatic Castrate-Resistant Prostate Cancer.
- Conditions
- Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,
- Trial name
- PYRUS (NCT01692262)
- Testing
- Intermittent dosing of AZD5363
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Metastatic Castration-Resistant Prostate Cancer
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
This study consists of a dose escalation study with an expansion phase to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and preliminary efficacy of exicorilant (CORT125281) in combination…
- Trial name
- NCT03437941
- Testing
- Exicorilant, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Corcept Therapeutics
Metastatic Castration-resistant Prostate Cancer
Phase 0/1 Study of 212Pb-NG001 in mCRPC
The purpose of this study is to evaluate the imaging feasibility and safety of 212Pb-NG001.
- Trial name
- NCT05725070
- Testing
- 212Pb-NG001
- Where
- Norway
- Volunteers
- 3 people
- Sponsor
- ARTBIO Inc.
Metastatic Castration-resistant Prostate Cancer, mCRPC
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2
100 mCi of [177Lu]Ludotadipep, the dose determined in the phase 1 clinical trial (FC705-1), was administered repeatedly up to 6 times at intervals of 8 weeks (±2 weeks) to patients with metastatic castration resistant prostate…
- Trial name
- LUCIDA_2 (NCT05579184)
- Testing
- [177Lu]Ludotadipep
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- FutureChem
Metastatic Castration-resistant Prostate Cancer
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)
The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new…
- Trial name
- NCT02987543
- Testing
- olaparib, enzalutamide, abiraterone acetate
- Where
- 204 sites in United States, Argentina and 18 more
- Volunteers
- 387 people
- Sponsor
- AstraZeneca
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis